Skip to main content

Table 2 Treatment-Emergent Adverse Events with Severity Grade 3 or 4 for Patients with CR Following First- or Second-Line Therapy (Safety Population)

From: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

  NR-CVac CVac SOC Total
(N = 7) (N = 26) (N = 24) (N = 57)
Patients with TEAE of Severity 3 or 4 0 (0 %) 7 (27 %) 2 (8 %) 9 (16 %)
Small intestinal obstruction 0 (0 %) 2 (8 %) 0 (0 %) 2 (4 %)
Abdominal pain 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Alanine aminotransferase increased 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Arthralgia 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Bunion 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Cough 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Diarrhea 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Disease Progression 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Escherichia urinary tract infection 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Febrile neutropenia 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Gamma-glutamyltransferase increased 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Hand fracture 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Headache 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Meniscus lesion 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Metastases to liver 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Ovarian epithelial cancer metastatic 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Pruritus generalized 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Sinusitis 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)